

## Electronic Supplementary Material

Prebiotic effect of inulin-type fructans on fecal microbiota and short-chain fatty acids in type 2 diabetes: A randomized controlled trial

European Journal of Nutrition

Eline Birkeland<sup>1,2</sup>, Sedegheh Gharagozlian<sup>1</sup>, Kåre I. Birkeland<sup>2,3</sup>, Jørgen Valeur<sup>4,5</sup>, Ingrid Måge<sup>6</sup>, Ida Rud<sup>6</sup>, Anne-Marie Aas<sup>1,2</sup>

Ida Rud and Anne-Marie Aas share last authorship

<sup>1</sup>Section of Nutrition and Dietetics, Department of Clinical Service, Division of Medicine, Oslo University Hospital, Norway, <sup>2</sup>Institute of Clinical Medicine, University of Oslo, Norway <sup>3</sup>Department of Transplantation Medicine, Oslo University Hospital, Norway, <sup>4</sup>Department of Gastroenterology, Oslo University Hospital, Oslo, Norway, <sup>5</sup>Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway, <sup>6</sup>Nofima - Norwegian Institute of Food, Fisheries and Aquaculture Research, Ås, Norway.

Corresponding author: Eline Birkeland, eline.birkeland@ous-hf.no

**Online Resource 2.** ANOVA table and post-hoc level comparisons of the intervention design at different taxonomic levels.

	Multivariate Analysis of Variance (ASCA)			Post-hoc comparisons between Treatment x Week levels (PLS-DA)	
	Explained variance (%)			Explained variance (%) (cross-validated)	
Taxonomic level	Between subjects effect	Treatment x Week effect	Error	Treatment vs baseline/placebo	Baseline1 vs baseline2
L2	64.9 (p < 0.001)	2.2 (p = 0.091)	32.9	8.0	0.0
L4	65.7 (p < 0.001)	1.7 (p = 0.195)	32.5	0.0	0.0
L5	73.9 (p < 0.001)	1.1 (p = 0.457)	25.0	0.0	0.0
L6	73.2 (p < 0.001)	1.3 (p = 0.123)	25.5	6.0	0.0
L7	69.9 (p < 0.001)	1.5 (p = 0.049)	28.6	43.0	0.0